Taiwan has the potential to become a biomedical powerhouse in three years if the nation can continue to provide capital access to the industry, Chen Lan-bo (陳良博), cofounder of AIDS drug developer TaiMed Biologics Inc (中裕新藥), said last week.
Chen, an emeritus at Harvard Medical School, expects new drug companies in Taiwan could generate US$30 billion in revenue a year, with 10 companies, including TaiMed, OBI Pharma Inc (台灣浩鼎), Taiwan Liposome Co (台灣微脂體) and TaiGen Biotechnology Co (太景生技) able to acquire drug permits over the next three years.
Chen said his optimism should encourage investors, including government officials, to continue funding the industry and help attract major global pharmaceutical companies to seek for potential collaboration opportunities here.
MIRACLE
“It is a miracle for the capital market in Taiwan to become so supportive to the industry,” Chen said at a press conference on Saturday. “The phenomenon was totally unimaginable five to 10 years ago.”
In 2007, Chen and David Ho (何大一), well known for his study on combination therapy to treat AIDS, founded TaiMed in Taipei with investments from the state-run National Development Fund and the private sector.
Chen said funding is especially important to the industry, but relying on stock markets might not be enough. Rather, private hedge funds or the government should also play a role to offer money in need, he said.
“The government should establish rules for local insurance companies to invest their money in the biotechnology industry, as pension funds in the US are one of the main sources for capital,” he said.
INVESTMENT TALKS
About eight years ago, when Chen worked as senior scientific adviser for New York-based hedge fund Caxton Health Holdings, he had talks with nine Taiwanese insurance companies about investing in biomedical firms.
However, their investment plans were denied by the government, as officials perceived making investment in the industry as too risky, he said.
According to Chen, the nine companies had idle funds of about NT$8 trillion to NT$15 trillion (US$267 trillion to US$501 trillion) at that time, and even 1 percent of the money would be helpful to many biomedical firms.
Asked whether there is a bubble for the biomedical industry in Taiwan, Chen said the same question was asked in the US in the past when the industry began to flourish.
“However, for the industry in Taiwan to really make some achievements, to have enough people believing the industry would be successful is a precondition,” he said.
At the conference on Saturday, Ho, the scientific director and CEO of Aaron Diamond AIDS Research Center at the Rockefeller University, said that for Taiwan to have a strong biotechnology industry like the US, the nation should adopt a more bottom-up decisionmaking process to allow scientists “the freedom to roam and explore,” rather than requiring them to focus on topics policymakers and officials are interested in.
LEARNING FROM FLIES
“We learn something about the immune system from the studies of flies. A fruit fly taught us that there is a whole part of our immune system that 20 years ago we didn’t know anything about,” Ho said. “It is uninhibited research that makes scientific breakthroughs, and important products emerge from those breakthroughs.”
Unlike companies in South Korea, where large private firms are backed by the government, the success of small biotechnology firms in Taiwan is the result of contributions from private citizens, including Samuel Yin (尹衍樑), chairman of Ruentex Group (潤泰集團) who helped fund TaiMed, Ho said, adding that although these firms are still young and deliver “more promises than products,” they will be more successful in coming years.
BYPASSING CHINA TARIFFS: In the first five months of this year, Foxconn sent US$4.4bn of iPhones to the US from India, compared with US$3.7bn in the whole of last year Nearly all the iPhones exported by Foxconn Technology Group (富士康科技集團) from India went to the US between March and last month, customs data showed, far above last year’s average of 50 percent and a clear sign of Apple Inc’s efforts to bypass high US tariffs imposed on China. The numbers, being reported by Reuters for the first time, show that Apple has realigned its India exports to almost exclusively serve the US market, when previously the devices were more widely distributed to nations including the Netherlands and the Czech Republic. During March to last month, Foxconn, known as Hon Hai Precision Industry
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) and the University of Tokyo (UTokyo) yesterday announced the launch of the TSMC-UTokyo Lab to promote advanced semiconductor research, education and talent development. The lab is TSMC’s first laboratory collaboration with a university outside Taiwan, the company said in a statement. The lab would leverage “the extensive knowledge, experience, and creativity” of both institutions, the company said. It is located in the Asano Section of UTokyo’s Hongo, Tokyo, campus and would be managed by UTokyo faculty, guided by directors from UTokyo and TSMC, the company said. TSMC began working with UTokyo in 2019, resulting in 21 research projects,
Ashton Hall’s morning routine involves dunking his head in iced Saratoga Spring Water. For the company that sells the bottled water — Hall’s brand of choice for drinking, brushing his teeth and submerging himself — that is fantastic news. “We’re so thankful to this incredible fitness influencer called Ashton Hall,” Saratoga owner Primo Brands Corp’s CEO Robbert Rietbroek said on an earnings call after Hall’s morning routine video went viral. “He really helped put our brand on the map.” Primo Brands, which was not affiliated with Hall when he made his video, is among the increasing number of companies benefiting from influencer
Quanta Computer Inc (廣達) chairman Barry Lam (林百里) yesterday expressed a downbeat view about the prospects of humanoid robots, given high manufacturing costs and a lack of target customers. Despite rising demand and high expectations for humanoid robots, high research-and-development costs and uncertain profitability remain major concerns, Lam told reporters following the company’s annual shareholders’ meeting in Taoyuan. “Since it seems a bit unworthy to use such high-cost robots to do household chores, I believe robots designed for specific purposes would be more valuable and present a better business opportunity,” Lam said Instead of investing in humanoid robots, Quanta has opted to invest